Press release
Ulcerative Colitis Clinical Trials | A Drug Pipeline Analysis Report 2024 | Oppilan Pharma, Genentech, Teva Branded Pharmaceutical, Boehringer Ingelheim, Sorriso Pharmaceuticals, Reistone Biopharma, Celgene, AnaptysBio, Rise Therapeutics, Merck, AltruBio,
Ulcerative Colitis Clinical Trials
Request for a sample report @ https://www.delveinsight.com/report-store/ulcerative-colitis-uc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Key Takeaways from the Ulcerative Colitis Pipeline Report
Over 75+ Ulcerative Colitis pipeline therapies are in various stages of development, and their anticipated acceptance in the Ulcerative Colitis market would significantly increase market revenue.
Leading Ulcerative Colitis companies developing novel drug candidates to improve the Ulcerative Colitis treatment landscape include Eli Lilly and Company, AbbVie, Pfizer, and others.
Promising Ulcerative Colitis pipeline therapies in various stages of development include Mirikizumab, Risankizumab, Etrasimod, and others.
Ulcerative Colitis Overview
Ulcerative colitis is an idiopathic inflammatory condition of the colon, characterized by diffuse friability and superficial erosions on the colonic wall, often associated with bleeding. It is the most common form of inflammatory bowel disease worldwide. The inflammation is typically restricted to the mucosa and submucosa of the colon, extending proximally in a continuous manner. In the United States, ulcerative colitis accounts for a quarter-million provider visits annually, with medical costs directly related to the disease estimated to exceed four billion dollars annually.
The specific cause of inflammatory bowel disease is not known, but there appears to be a primary genetic component, as the most important independent risk factor is a family history of the disease, affecting 8% to 14% of patients. A first-degree relative of a patient with ulcerative colitis has a four times higher risk of developing the disease. Additionally, ulcerative colitis has a higher incidence in Jewish populations compared to other ethnicities.
The pathophysiology of ulcerative colitis involves defects in the epithelial barrier, immune response, leukocyte recruitment, and microflora of the colon. The epithelial barrier defect includes abnormalities in colonic mucin and possibly tight junctions, leading to increased uptake of luminal antigens. The lamina propria of the mucosa also has an increased number of activated and mature dendritic cells, which include a large number of toll-like receptors (TLR), specifically TLR2 and TLR4. There is also an atypical T-helper (Th) cell response in patients with ulcerative colitis, particularly Th2, which exerts a cytotoxic response against epithelial cells.
Leukocyte recruitment is affected on two fronts. There is an upregulated release of the chemoattractant CXCL8 in ulcerative colitis, leading to the recruitment of leukocytes to the mucosa from systemic circulation. Additionally, there is an upregulation of mucosal cellular adhesion molecule-1 (Mad-CAM1) on the endothelium of mucosal blood vessels, promoting leukocyte adhesion and extravasation into mucosal tissue.
Studies have shown that enteric microflora plays a significant role in the pathogenesis and severity of inflammation and disease phenotype. Ulcerative colitis seems to result, in part, from a homeostatic imbalance between enteric microflora and the host's mucosal immunity, leading to an aberrant response to non-pathogenic bacteria.
Download a sample page report to know more about ulcerative colitis pipeline segment @ https://www.delveinsight.com/report-store/ulcerative-colitis-uc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Ulcerative Colitis Emerging Drugs
Obefazimod: Abivax
Obefazimod is an oral small-molecule drug candidate in clinical development for the treatment of moderately to severely active ulcerative colitis (UC) and has demonstrated anti-inflammatory activity in preclinical studies and in both Phase IIa and Phase IIb clinical trials. Currently, the drug is in Phase III stage of its clinical trial for the treatment of ulcerative colitis.
ABBV-668: AbbVie
ABBV-668 is under development for the treatment of crohn's disease, unspecified immunological disorders and ulcerative colitis. The drug candidate acts by targeting receptor interacting serine/threonine protein kinase 1 (RIPK1). It is administered through oral route. Currently, the drug is in Phase II stage of its clinical trial for the treatment of ulcerative colitis.
TEV-48574: Teva Pharmaceutical
Anti-TL1A (TEV-'574) is a potentially best-in-class human IgG1 monoclonal antibody that targets tumor necrosis factor (TNF)-like ligand 1A (TL1A), also known as TNF superfamily member 15. TL1A signaling is believed to amplify inflammation and drives fibrosis associated with asthma and inflammatory bowel disease (IBD); thus, targeting TL1A with TEV-'574 may mitigate the over-active immune response in these conditions. Anti-TL1A (TEV-'574) is currently in Phase 2b clinical trials for the treatment of ulcerative colitis (UD) and Crohn's disease (CD), two types of inflammatory bowel disease. The safety and efficacy of anti-TL1A (TEV-'574) have not been reviewed by any regulatory authority. Currently, the drug is in Phase II stage of its clinical trial for the treatment of ulcerative colitis.
SOR102: Sorriso Pharmaceuticals
SOR102 combines anti-TNF and anti-IL-23 vorabodies into a single dual-acting molecule a trypsin cleavable linker releases the monomers to independently engage their targets throughout intestinal tissue. SOR102 provides combination therapy locally within inflamed tissue with minimal risk of systemic immunosuppression. Overall benefits of dual targeting approach increased efficacy through blockade of different inflammatory mechanisms of IBD. Currently, the drug is in Phase I stage of its clinical trial for the treatment of ulcerative colitis.
Discover more about the emerging Ulcerative Colitis drugs @ https://www.delveinsight.com/sample-request/ulcerative-colitis-uc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Ulcerative Colitis Key Companies
Eli Lilly and Company
AbbVie
Pfizer
Ulcerative Colitis Pipeline Therapies
Mirikizumab
Risankizumab
Etrasimod
Ulcerative Colitis Pipeline Therapeutics Assessment
By development stage
By product type
By route of administration
By molecule type
By MOA type
Scope of the Ulcerative Colitis Pipeline Report
Coverage: Global
Key Ulcerative Colitis Companies: Eli Lilly and Company, AbbVie, Pfizer, and others
Key Ulcerative Colitis Pipeline Therapies: Mirikizumab, Risankizumab, Etrasimod, and others
Find out more about the Ulcerative Colitis treatment options in development @ https://www.delveinsight.com/sample-request/ulcerative-colitis-uc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Table of Contents
1. Introduction
2. Executive Summary
3. Overview
4. Pipeline Therapeutics
5. Late-Stage Products (Phase III)
6. Mid-Stage Products (Phase II)
7. Early Stage Products (Phase I/II)
8. Preclinical Stage Products
9. Discovery Stage Products
10. Therapeutic Assessment
11. Inactive Products
12. Collaborations Assessment- Licensing / Partnering / Funding
13. Unmet Needs
14. Market Drivers and Barriers
15. Appendix
16. About DelveInsight
Trending Reports By DelveInsight:
Functional Constipation Market
https://www.delveinsight.com/report-store/chronic-constipation-market
Lebers Hereditary Optic Neuropathy Lhon Market https://www.delveinsight.com/report-store/lebers-hereditary-optic-neuropathy-lhon-market
Gastric Neuroendocrine Tumors Market
https://www.delveinsight.com/report-store/gastric-neuroendocrine-tumors-market
Immune Thrombocytopenic Purpura Market
https://www.delveinsight.com/report-store/immune-thrombocytopenia-itp-market
Visceral Pain Associated With GI Disorders Market
https://www.delveinsight.com/report-store/visceral-pain-associated-with-gi-disorders-market
Bullous Pemphigoid Market
https://www.delveinsight.com/report-store/bullous-pemphigoid-market
Cyclin-dependent Kinase-like 5 Deficiency Disorder Market https://www.delveinsight.com/infographics/cyclin-dependent-kinase-like-5-cdkl5-deficiency-disorder-market
Myocarditis Market
https://www.delveinsight.com/report-store/myocarditis-market
Recurrent Blood Clots Market
https://www.delveinsight.com/report-store/recurrent-blood-clots-thrombophilia-market
Zollinger-ellison Syndrome Market
https://www.delveinsight.com/report-store/zollinger-ellison-syndrome-market
Age-related Hearing Loss Medical Device Market
https://www.delveinsight.com/blog/age-related-hearing-loss-device-market
Heart Sounds Sensors Market
https://www.delveinsight.com/report-store/heart-sounds-sensors-electronic-stethoscope-market
Hypoplastic Left Heart Syndrome Hlhs Market
https://www.delveinsight.com/report-store/hypoplastic-left-heart-syndrome-market
Infectious Arthritis/Septic Arthritis Market
https://www.delveinsight.com/report-store/infectious-arthritisseptic-arthritis-market
Plasmacytoma Market
https://www.delveinsight.com/report-store/plasmacytoma-market
Agoraphobia Market
https://www.delveinsight.com/report-store/agoraphobia-market
Clinically Isolated Syndrome CIS Market
https://www.delveinsight.com/report-store/clinically-isolated-syndrome-cis-market
Fucosidosis Market
https://www.delveinsight.com/report-store/fucosidosis-market
Major Depressive Disorder Market
https://www.delveinsight.com/report-store/major-depressive-disorder-market
Neuronal Ceroid-lipofuscinoses Market
https://www.delveinsight.com/report-store/neuronal-ceroid-lipofuscinoses-cln1-disease-market
Orthotic Devices Market
https://www.delveinsight.com/report-store/orthotic-devices-market
Contact Us
Kritika Rehani
info@delveinsight.com
+14699457679
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Ulcerative Colitis Clinical Trials | A Drug Pipeline Analysis Report 2024 | Oppilan Pharma, Genentech, Teva Branded Pharmaceutical, Boehringer Ingelheim, Sorriso Pharmaceuticals, Reistone Biopharma, Celgene, AnaptysBio, Rise Therapeutics, Merck, AltruBio, here
News-ID: 3631702 • Views: …
More Releases from DelveInsight Business Research LLP
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead…
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight…
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market…
More Releases for Ulcerative
Ulcerative Colitis Pipeline Insights Report | DelveInsight
DelveInsight's, "Ulcerative Colitis Pipeline Insight" report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Ulcerative Colitis Pipeline Landscape. It covers the Ulcerative Colitis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Ulcerative Colitis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay…
Novel Therapies for Ulcerative Colitis Patients
"The Business Research Company recently released a comprehensive report on the Global Ulcerative Colitis Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
According to The Business Research Company's, The ulcerative colitis market size…
Ulcerative Colitis Market - Breaking Barriers, Transforming Digestive Health: Ul …
Newark, New Castle, USA: The "Ulcerative Colitis Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Ulcerative Colitis Market: https://www.growthplusreports.com/report/ulcerative-colitis-market/8815
This latest report researches the industry structure, sales, revenue,…
Ulcerative Colitis Market - Breaking Barriers, Empowering Resilience: Transformi …
Newark, New Castle, USA - new report, titled Ulcerative Colitis Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Ulcerative Colitis market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Ulcerative Colitis market. The report offers an overview of the market, which…
Ulcerative Colitis - Drug Pipeline Landscape, 2023
Global Ulcerative Colitis Market report from Global Insight Services is the single authoritative source of intelligence on ulcerative colitis market. The report will provide you with analysis of impact of latest market disruptions such as Russia-Ukraine war and Covid-19 on the market. Report provides qualitative analysis of the market using various frameworks such as Porters' and PESTLE analysis. Report includes in-depth segmentation and market size data by categories, product types,…
Ulcerative Colitis Market
Ulcerative colitis is the most common type of inflammatory bowel disease that affects the colon (lining of the large intestine) and rectum. The inflammation produces tiny sores called ulcers. These disease can affect people of any age, though prevalence is especially high among people under 30 years of age. The major symptoms of this disease are diarrhea, belly pain/cramps, bleeding from the rectum, also other indications are sudden and unexplained…
